Goldman Sachs initiated coverage of Bicara Therapeutics (BCAX) with a Not Rated, saying ficerafusp could beat pembro in first-line HPV-negative head and neck squamous cell carcinoma, “but has shortcomings” in the “race for best-in-class.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX: